

# RESULT IMPACT

February 14, 2023



Moneywise. Be wise.

## Today's result, its estimates and estimated impact on price movement

Company NSE Symbol	Company Name	Estimates	Estimated Impact
EICHERMOT	Eicher Motors Limited	The result is expected to be +ve on account of good revenue growth during this quarter due to good volume growth and price hikes. EBITDA is likely to improve supported by lower commodity prices and operating leverage. Management insight to watch for is demand expectations across the market and margins	Positive
GRASIM	Grasim Industries Limited	The result is expected to be flat to +ve on account of positive performance during this quarter due to healthy revenue growth supported by double-digit volume. EBITDA's margin is likely to be flat due to higher costs in its viscose business	Positive
BOSCH	BOSCH Limited	The result is expected to be +ve driven by healthy top-line growth on account of driven by strong growth in the automotive segment. The growth in the automotive segment came on the back of smoother semiconductor chip supply. EBITDA is likely to improve due to a rich product mix which may help the company to offset the impact of raw material price rise	Positive
SIEMENS	Siemens Limited	The result is expected to be +ve driven by healthy order book, strong presence in diversified industries and product localisation which may help the company to improve its earnings and margins.	Positive
APOLLOHOSP	Apollo hospital Enterprises Limited	The result is expected to be flat to -ve driven by muted performance by Healthcare Services and Pharmacy Distribution but clinics segment may show negative growth. Margins are expected to decline too driven by lower overall occupancy level.	Negative
O N G C	Oil & Natural Gas Corporation Limited	The result is expected to be flat driven by decline in margins on sequential basis due to the government's windfall gains tax which would also reduce average realization. Volumes too are expected to remain muted, in line with recent trends.	Sideways
BIOCON	Biocon Limited	The result is expected to flat to +ve driven by moderate growth in revenues due to good performance by Biosimilars and Generics. EBITDA and margins are likely to improve slightly supported by cost management.	Sideways

**Disclaimer:** This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s) in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance of this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies); or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. SMC is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, MSEI (Metropolitan Stock Exchange of India Ltd) and M/s SMC Comtrade Ltd is a registered member of National Commodity and Derivative Exchange Limited and Multi Commodity Exchanges of India and other commodity exchanges in India. SMC is also registered as a Depository Participant with CDSL and NSDL. SMC's other associates are registered as Merchant Bankers, Portfolio Managers, NBFC with SEBI and Reserve Bank of India. It also has registration with AMFI as a Mutual Fund Distributor.

SMC is a SEBI registered Research Analyst having registration number INH100001849. SMC or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing/dealing in securities market. SMC or its associates or its Research Analyst or his relatives do not hold any financial interest in the subject company interest at the time of publication of this Report. SMC or its associates or its Research Analyst or his relatives do not hold any actual/beneficial ownership of more than 1% (one percent) in the subject company, at the end of the month immediately preceding the date of publication of this Report. SMC or its associates its Research Analyst or his relatives does not have any material conflict of interest at the time of publication of this Report.

SMC or its associates/analyst has not received any compensation from the subject company covered by the Research Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the subject company covered by analyst or third party in connection with the present Research Report. The Research Analyst has not served as an officer, director or employee of the subject company covered by him/her and SMC has not been engaged in the market making activity for the subject company covered by the Research Analyst in this report.

The views expressed by the Research Analyst in this Report are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty expressly or impliedly to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the subject company.